Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:38:27.385Z.
Consensus retrieved: 2026-10-06T17:18:32.673Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:38:27.385Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2b785bc55096390182f69d3a0e2d020d3bb9b84e75505e860cfcb21a76503d6
Forward PE Ratio (N/A) = Dated Quote Price ($4.27) / Consensus Forward EPS ($-0.33)
FORWARD PE RATIO
N/A
TriSalus Life Sciences, Inc.
Market Cap
$262.92M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $262.92M | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.27, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.33 | $-0.36 – $-0.31 | 3 | n/m |
| 2027-12-31 | $-0.26 | $-0.29 – $-0.25 | 3 | n/m |
| 2028-12-31 | $0.13 | $-0.18 – $0.59 | 4 | 33.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
